Effective combination therapies for preventing and treating highly prevalent human diseases: cancers, heart-failure, tuberculosis and malaria

Abstract

Methyl jasmonate has emerged as a tool for the selective activation of sarcoplasmic reticulum Ca²⁺-ATPase in slow-twitch skeletal muscle and a regulator of calcium homeostasis in this tissue.  An invention which provided the technology for the prevention of skeletal muscle degeneration commonly caused by malnutrition, cancer, tuberculosis and the acquired immune deficiency syndrome (AIDS), has been patented (US Patents 6,465,021 of October 15, 2002 and 6,887,499 of May 3, 2005). The second object of the invention is to provide a formulation for preventing the skeletal muscle wasting that does not adversely affect calcium homeostasis or induce additional oxidative stress of the muscle cells. The formulation includes at least one of the jasmonate family of stress hormones in an effective manner, at least one of the flavonoid antioxidants, and carnitine.

     Since 2006 and after the release of the invention, there have been continuous positive support and provision of scientific evidence from numerous researchers, in various parts of the world, justifying the inclusion of each of the three components of the formulation. An emerging scenario suggests that inhibitors of 5-lipoxygenase (5-LOX) and cycloxygenase-2 (COX-2) could be useful in preventing and treating diseases such as cancer, heart failure and malaria.